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To determine Implanon acceptance, the group of women accepting it, complications, indications
for discontinuation; and report an initial experience with the method.
This was a retrospective observational study of Implanon®, a single rod, long acting, reversible
subdermal contraceptive implant system, containing the progestin etonogestrel, which was introduced in Jos,
Nigeria, in May 2006.
Implanon capsules were accepted by 404 clients constituting 13.4% of acceptors of all contraceptive
methods. The average age, parity and number of living children to the acceptors were 32.1 years, 3.6 and 3.3
respectively. About three-quarters (76.0%) of the women had secondary and tertiary education. Seventy-three
(18.1%) of the women were taking a modern contraceptive method for the first time. There were 7 removals
giving a high continuation rate of 98.3% in the first year. Menstrual disturbance was the commonest (57.1%)
indication for removal.
Implanon is an acceptable method of contraception among our women population.
Implant, Implanon, sub-dermal, Jos, Nigeria.
INTRODUCTION
Progestin contraceptive methods have been found to
be tolerated by many prospective clients for the
absence of estrogen effects . Implants (Norplant )
have been used in Jos for more than 2 decades as long
term hormonal contraceptive methods. They have
been found to be effective, safe, reversible, and
approved for use in Nigeria . Implanon® is a single
rod, long acting and reversible subdermal
contraceptive implant system containing the
progestin, etonogestrel, and developed by Organon.
The rod is made of ethylene vinyl-acetate holds 68
mg of etonogestrel, and meant to provide
contraception for 3 years. The rod measures 40 mm
in length, 2mm in diameter and is non-
biodegradable . Implanon® is the trademark of
Organon for etonogestrel. Etonogestrel is the active
metabolite of desogestrel and has been used in
combined oral contraceptives for many years with
established pharmacological effects . Implanon® is
suitable for a wide range of women particularly
women who want an easy-to-use contraceptive
method to postpone a first pregnancy, space
pregnancies or stop pregnancies using the reversible
long-term contraception on achieving the desired
family size . Implanon® may also be useful for
women who are not satisfied with other
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is contraindicated. The primary mechanism of action
of Implanon is through ovulation inhibition. In
addition, it also increases the viscosity of the cervical
mucus, thus having a dual contraceptive effect .
Ovulation is normally induced at mid-cycle LH surge
or peak. During Implanon use, this LH surge is
prevented. FSH levels are found to be normal which
means that there is still follicular development and
therefore normal endogenous estrogen levels . Serum
levels sufficient to inhibit ovulation are reached
within 8 hours. This means that it is efficacious within
the first day of insertion. Implanon provides effective
reliable and reversible contraception for a maximum
period of 3 years, after which time the implant should
be removed. It has proved to be extremely reliable.
The exceptional efficacy has been attributable mainly
to ovulation inhibition . Women want methods of
contraception that are effective, safe, convenient and
do not interfere with sexual life . The acceptability of
hormonal contraception depends mainly upon the
level of subjective side effects and the effect on
vaginal bleeding among others . The major
advantages of implants are their effectiveness,
convenience, safety, long-term contraceptive
protection that commence within 24 hours of
insertion and return of fertility almost immediately
after removal .
Implanon is inserted within the first 5 days of a
woman's natural cycle, day 1 being the first day of her









Indication for Removal Number (%)
Menstrual irregularities 4 (57.1)
Pregnant before insertion 2 (28.6)




Implanon, the women had between 0 and 8 living
children and an average of 3.3 children. The women
were of body weight of between 40 and 122 kg with
an average of 62.8 kg. One hundred and eleven,
(27.8%) of the women were above 70 kg in weight,
Table 1. About three-quarters (76.0%) of the
acceptors of the method had secondary and tertiary
education. Non-literate women constituted only
2.2%, Table 2. Two hundred and twenty eight
(56.4%) of the women desired more children on
discontinuation of the method, 170(42.1%) would
not want more children, while 6(1.5%) were
undecided.
There were 7 removals giving a continuation rate of
98.3% in the first year. The indications for removal
included side effects, 6 (menstrual disorders 4, acne
1, headache 1), husband's disapproval 2, and
pregnancy before insertion of the implant 2.
Menstrual disorders constituted over 50 percent of
the indication for removal in the 12 months of use.
Menstrual disturbance was the commonest indication




(*Two clients had more than one reason for removal
of the implant)
Parameters of Clients that Accepted
Implanon in Jos University Teaching Hospital
during the Study Period.
Literacy Level of the Women that
Accepted Implanon (N = 404).
The Indications for Removal of the
Implants within the Period (N = 7).





Not stated 11 (2.7)
Parameter Range Means
1. Age in years 19-47 32.1
2. Parity 0-11 3.6
3. Number of living children 0-8 3.3
4. Weight in Kilogrammes 40-122 62.8
combined oral contraceptive (COC), it should be
inserted preferably a day after the last active tablet of
the COC, but at least on the day following the usual
tablet-free interval or last placebo tablet of the COC.
When changing from a progestin-only method, it
may be inserted any day the woman is switching
from the pill. If she is switching from another
implant, it should be inserted on the day of its
removal. If switching from an injectable, it should be
inserted when the next injection is due. Following a
first trimester abortion, it should be done
immediately. If this is following childbirth or a
second trimester abortion, it should be on day 21-28
after delivery or second trimester abortion .
Regional Implanon® introduction for medical
professionals was organised in the family planning
unit of Jos University Teaching Hospital, Nigeria in
May 2006. The family planning unit is manned by 5
trained nursing staff and supervised by a consultant
Obstetrician/Gynaecologist. The unit is a type-A
facility, offering all forms of modern contraception.
The unit also provides Jadelle, the two-rod
contraceptive implant. All contraceptive methods
are sourced from the Federal Ministry of Health,
Abuja, and the implants cost patients two thousand
naira ($17) a set. Implants are the most expensive of
all the contraceptive methods in the centre including
the permanent forms. Counselling is offered and
informed consent is obtained prior to insertion of the
implant. Additional contraceptive choices are
available in the clinic and this helps couples to find
the contraceptive method that best suits their wishes
and preferences.
The objectives of the study were to determine the
acceptance of Implanon, the group of women
accepting it, the one-year continuation rate; and to
report our initial experience with the method.
This was a retrospective review of all clients that
accepted Implanon contraceptive method and other
modern contraceptive methods between May 2006
and April 2007 (12 months) in Jos University
Teaching Hospital, North-Central Nigeria. Socio-
demographic factors, removals, indications for
removal, insertion and post-insertion complications
were collated and evaluated. Analysis was done
using simple percentages.
Three thousand and fifteen (3,015) clients accepted
all contraceptive methods in the clinic within the
study period and out of these, 404 women accepted
Implanon, constituting 13.4%. The age of the women
ranged between 19 and 47 years, with an average of
32.1 years. The parity was from 0 to 11 with the
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62.8 kg, and about 27.8% of them were above 70 kg
body weight. Because of the reported good Pearl
index of Implanon, its insertion was not limited to
only women of 70 kg and below as initially applied
for Norplant. Weight was not a barrier to offering
Implanon to desiring patients in the unit. This is
because in a clinical trial of 130 women of body
weight above 70 kg for 2-3 years, not a single
pregnancy was recorded in that study . The women
were however counselled about the possibility of a
higher chance of failure in them compared with those
of lower body weight. Over three quarters of them
had a prior positive history of previous contraceptive
use.
Insertion complications like infection, expulsion,
bruising and induration did not occur and therefore
were not reported. The acceptors of Implanon came
from all other users of other contraceptive methods in
addition to those that had not used any form of
contraception before. Seven clients (1.7%) had the
Implanon removed within the study period giving a
continuation rate of 98.3% in the 12 months period.
That is higher than that reported for Norplant .
Prolonged bleeding episodes made up 20% of the
cases. This is similar to the 21.7% for Norplant
users . Menstrual disturbance, like in other
progestogens, was the commonest indication for
discontinuation of the method. The two clients that
were pregnant before insertion claimed to have seen
their menstrual periods, and pregnancy tests done
were negative in both of them just prior to insertion of
the implant. The clients escaped detection from the
pressure of a training session in the facility. Early
ultrasound scan dating of the pregnancies on follow-
up visit with the complaint of secondary
amenorrhoea showed that the pregnancies occurred
before the Implanon insertion. We need to be more
vigilant concerning client recruitment for insertion.
We will have to comply with the insertion within 5
days of menstruation as directed by the
manufacturers.
Women are accepting this new method of
contraception in this centre. The initial prospect is
good for the clients and providers alike. The method
appears to be a popular and promising long term sub-
dermal of contraceptive method amongst our women.
Continuation rate was high and side effects were few.
There is the need to begin to think of supply logistics
and sustainability if the method is to continue to enjoy
the patronage of prospective users. Women of
reproductive age wishing to prevent pregnancy have
a right to safe, effective and well-tolerated method of
contraception. This may just be one of such a method
for many clients. The following are pertinent issues to






Users of Implanon constituted about 13% of the
acceptors of contraception within the study period.
This is higher than the 5% documented for Norplant
in the same centre two years previously, and falls
within the range of less than 20% of users of
contraceptives in Nigeria . The acceptance of
implants for contraception is rising. This may be due
to increased awareness among the clients about the
method. Cost on the other hand, it was observed,
made the commodity inaccessible to all desiring
patients. The most common side effect of implants is
the disruption of the menstrual cycle . This was the
same in the study accounting for over 50% of the
indications for discontinuation/removal of the
implants. It is also known that menstrual disturbance
also occurs in untreated women of reproductive age
with amenorrhoea occurring in about 1% of women,
infrequent bleeding in about 8% and frequent and
prolonged bleeding in less than 0.1% . The use of
Implanon is supported in any client who knows what
to expect from it in terms of efficacy, convenience
and limitations like irregular menstrual bleeding.
Counselling of the clients about the bleeding
disorders helps to reduce the discontinuation rate.
About one-fifth of the women were taking a
contraceptive method for the first time while four-
fifths of them had been on one method of
contraception or the other and were only switching
over to Implanon sub-dermal implants. The implants
thus offer women an additional 'contraceptive
method mix' to choose from for the new patients and
the opportunity to change method for patients that
had been on other modern methods of contraception.
A little over 50% percent of the women were using
the method for the limitation of family size. As many
as 42% of the clients would not want any more
children but opted for Implanon instead of a
permanent method. This means that their family size
had been reached but who were still considering
sterilization or permanent form of contraception
The socio-demographic characteristics of Implanon
users revealed that they were young with average age
of 32.1 years. They had an average parity of 3.6,
while the average number of living children was 3.3.
These values are lower than the 6.0 and 4.4 for
Norplant acceptors for parity and number of living
children respectively in a previous study . Some of
the clients were yet to have a child (parity zero).
About 56.4% had the desire for more children after
the removal of the implants. All the women were
married and in stable family relationships. Majority
(76%) of the patients were of tertiary and secondary
education. Non-literate women appear to be
suspicious of new methods and therefore shunned
the method, constituting less than 3% of the





Nigerian Journal of Clinical Practice March 2010, Vol.13(1) Experience With Implanon Mutihir & Nyango 30
5.
6. Ladipo OA. Akinso S.
7. Croxatto HB, Makarainen L.





13. Faundes A, Alvarez F, Branche V, Jimenez E,
Tejada AS.
14. Aisien AO, Sagay AS, Imade GE, Ujay IAO,
Nnana OU.
Organon. Insertion, localization and removal of
Implanon. Implanon Product Monograph. N. V.
Organon, 2005c; 47-54.
A Contraceptive
Implants. African Journal of Reproductive
Health, 2005; 9: 16-23.
The pharmaco-
dynamics and efficacy of Implanon: An
overview of the data. Contraception, 1998; 58:
91-97.
Implanon: A review of
Clinical Studies. British Journal of Family
Planning, 1999; 24: 3-16.
Progestin Implants for female
contraception. Contraception, 2002; 65: 15-19.
Organon. Introduction and clinical profile of
Implanon. Implanon Product Monograph. N. V.
Organon, 2002b; 7-8.
EngenderHealth. The future of contraceptive
implants in Nigeria. EngenderHealth Activity
Brief, Lagos, Nigeria.April, 2002; 1-8.
Long-acting methods of
contraception. British Medical Journal, 1994;
308: 991-992.
Hormonal changes associated with
bleeding during low dose progestogen
contraception delivered by Norplant subdermal
implants.Adv Contraception, 1991; 7: 1-10.
Changes in Menstrual and
haematological indices among Norplant
Acceptors. Contraception, 2000; 61: 283-286.
Close monitoring and follow-up of these clients over
a longer period to determine client satisfaction with
the method, side effects, safety and effectiveness of
Implanon among Nigerian women. Collaborative
studies should be conducted across the country to
determine the acceptability of Implanon among the
different ethnic groups. Structures for sustainability
should be put in place supported by legislation and
strong government policy to make the Implanon
available to clients at all times. Barriers to
accessibility such as cost should be addressed in
order for all desiring clients to benefit from the
method.
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of the implants and record keeping. I remain
indebted to the officials of the Federal Ministry of
Health for their support.
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